New drug combo targets Tough-to-Treat colorectal cancer in phase 3 trial
Disease control
Recruiting now
This study tests whether combining two drugs, tunlametinib and vemurafenib, can help people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation). About 165 adults aged 18 to 70 with metastatic disease will receive the combination to see if it slows can…
Phase: PHASE3 • Sponsor: Shanghai Kechow Pharma, Inc. • Aim: Disease control
Last updated May 17, 2026 04:47 UTC